NEW YORK (GenomeWeb News) – Richard Shippy has joined Illumina as director of global product marketing for clinical genomics within the San Diego firm's diagnostics division.

In his new role, Shippy will be responsible for product marketing activities covering clinical genomics with an emphasis on cytogenomics, and will be working with BlueGnome to advance array designs for that market segment. Illumina acquired BlueGnome in September.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.